Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Medolife Rx Announces New Extraction Facility and Scientific Team in Place
May 13, 2021 08:00 ET | Source: Quanta, Inc.
...
BURBANK, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has secured a new extraction facility in the Dominican Republic (DR) as well as onboarded scientific staff in order to increase production of Escozine® to meet rising demand following the Company’s recent product registration as a natural alternative cancer treatment.
As announced, the Company has been scaling production of its lead drug candidate Escozine®, which is derived from peptides found in scorpions that are then polarized through a patented process to increase efficacy. The peptides are extracted from the scorpions in a safe and humane way through a scientific process conducted in a clean laboratory setting. As such, the Company worked with the Ministry of Environment and Natural Resources in the DR to identify and garner the necessary approvals for an extraction facility to support this production. After receiving said approvals, the Company has now onboarded a scientific team at the facility who is trained and ready to begin extraction of the peptides. This team will increase Medolife’s current capacity by around ten-fold, with the capability of adding a night shift and later doubling that increase in production.
“Our goal is to not only sell approved pharmaceutical medicines and functional wellness products, but to own our supply chain, which is rare in our space, and this facility adds to that construct,” said Medolife CEO Dr. Arthur Mikaelian. “Paired with our first-of-its-kind scorpion reservation, this extraction facility will allow us to produce the peptides necessary to create most of our pharmaceutical products in-house. That means increased margins and a decreased final cost, creating a larger market opportunity in under-developed or developing nations.”
Medolife has been researching Escozine® as a potential treatment for COVID-19 in clinical research programs in both the United States and the DR. The Company has completed numerous safety and efficacy studies on the drug, and filed a final data set with the US Food and Drug Administration (FDA) as it relates to an Investigational New Drug (IND) filing on Escozine®. The Company is in the process of registration for medical ethics committee approval to conduct double-blind placebo human studies on Escozine®, which would mark a substantial step forward in Escozine’s path toward worldwide registration and adoption.
Furthermore, the Company will continue to operate in the nutraceutical space with consumer products in general wellness, stress relief, anxiety treatment, and pain management.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Tom Nelson
https://ir.quantrx.com/
818-659-8052
Kyle Porter
medolife@cmwmedia.com
858-264-6600
www.cmwmedia.com
Link
Gold Morning my friend!
New Here!
$$$$$$ MY FRIEND $_$
$QNTA
AMEN!!!
$QNTA
IM SO HAPPY TO BE HERE...
$QNTA
IDK HOW PPL ARE SELLING THIS AT THIS PRICE, I´M SO HAPPY TO WAIT AND SEE HOW THIS MOVE UP SOON! :D
WOW, AND I JUST HAVE 2255 :´(
CONGRATS BRO!!!
Protext Mobility releases video interview w/ CEO discussing Cannabis Biosciences acquisition, science behind Phytofare, cannabis research, and exciting future of TXTM.
YOUTUBE VIDEO INTERVIEW TXTM 03/28/2017
Yeah, this sucks... but well anyways, What are we can do? :/
$TXTM
My morning was good until I saw the pps decreasing... I don't know if I lost my faith in this, but I am absolutely sure the day today, let down a lot of people, include me... :/
$TXTM
I would like to see that!
$TXTM
This is just amazing... Great news and the pps is down! What's wrong with you people?
$TXTM
NEWS OUT TXTM (03/27/2017): Protext Mobility Announces Acquisition of Cannabis Biosciences Inc.
OTC Markets/Plandai News...
BOCA RATON, FL -- (Marketwired) -- 03/27/17 -- Protext Mobility, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications for the highly bioavailable Phytofare® catechin complex, today announced its acquisition of Cannabis Biosciences Inc. from Plandaí Biotechnology Inc. Under the terms of the transaction, Protext acquired 100% of the capital stock of Cannabis Biosciences in exchange for 50 million shares of its common stock. Plandaí has indicated that the shares acquired from Protext will be distributed to Plandaí shareholders as a stock dividend. Protext will now operate its two wholly owned subsidiaries as independent operating businesses. The new business unit, Cannabis Biosciences, will focus on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing. Plandaí Biotechnology South Africa, the other business unit, is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. The Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex produced from green tea grown on the Senteeko estate.
Cannabis Biosciences was formed and incorporated by Plandaí Biotechnology in 2013 to legally develop non-psychoactive medicines from live cannabis plant. Using Plandaí's proprietary processing and extraction technology, the company intends to commence investigations in conjunction with independent researchers to develop and validate a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The hypothesis is that the resultant extract will have similar, superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive. Several third-party investigations have shown that the precursor acid forms THC-A and THC-B in live cannabis leaf are inherently non-psychoactive and that the process of drying and heating the leaf metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.
Roger Baylis-Duffield, Chief Executive Officer of Protext, commented, "Where most pharma companies have chosen to focus on the non-psychoactive CBD chemical, we believe that this strategy limits the potential medical benefits. Recent third party studies have demonstrated the synergistic value of retaining the full chemical profile of cannabis. Our objective is to validate Cannabis Biosciences cannabis extracts to be not only full profile but also non-psychoactive, which will give researchers all of the benefits of cannabis without the unwanted side effects. The acquisition of Cannabis Biosciences by Protext properly aligns our pharmaceutical research under one roof, allowing us to further our cannabis studies as we strive to create a cannabis extract that can increase the well-being and potentially improve the lives of so many people."
We encourage our investors and shareholders to connect and engage with us through social media. You can find us on the following;
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
About Protext Mobility, Inc. Protext Mobility, operates two wholly owned subsidiaries; Plandaí Biotechnology South Africa (SA) and Cannabis Biosciences. The Company is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Through its wholly owned subsidiary Plandaí Biotechnology SA, the Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex, which was developed by Plandaí Biotechnology, Inc. Phytofare® is a highly bioavailable extract produced from live green tea leaves. Our initial product, Phytofare® Catechin Complex, has been clinically shown to have 10 times greater bioavailability over generic catechin extracts. What this means is that Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours. Plandaí grows green tea on its 7,500 acre Senteeko estate in South Africa, where it produces the proprietary Phytofare® catechin extract in-house, allowing the Company a continuity of supply as well as quality control throughout the entire process. Targeted applications for the Company's products include arthritis, inflammation, anti-viral, and diabetes-related metabolic syndromes.
Please visit http://www.protextm.co for further information.
About Cannabis Biosciences The Company is actively pursuing government licenses and permits that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.
CONTACT INFORMATION
Protext Mobility, Inc.
Info@protextm.co
Contact: (435)881-3611
Source: Protext Mobility, Inc.
NEWS OUT (03/27/2017): Protext Mobility Announces Acquisition of Cannabis Biosciences Inc.
BOCA RATON, FL -- (Marketwired) -- 03/27/17 -- Protext Mobility, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications for the highly bioavailable Phytofare® catechin complex, today announced its acquisition of Cannabis Biosciences Inc. from Plandaí Biotechnology Inc. Under the terms of the transaction, Protext acquired 100% of the capital stock of Cannabis Biosciences in exchange for 50 million shares of its common stock. Plandaí has indicated that the shares acquired from Protext will be distributed to Plandaí shareholders as a stock dividend. Protext will now operate its two wholly owned subsidiaries as independent operating businesses. The new business unit, Cannabis Biosciences, will focus on developing cannabis extracts under legal government licenses and permits which the Company is currently pursuing. Plandaí Biotechnology South Africa, the other business unit, is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. The Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex produced from green tea grown on the Senteeko estate.
Cannabis Biosciences was formed and incorporated by Plandaí Biotechnology in 2013 to legally develop non-psychoactive medicines from live cannabis plant. Using Plandaí's proprietary processing and extraction technology, the company intends to commence investigations in conjunction with independent researchers to develop and validate a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The hypothesis is that the resultant extract will have similar, superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive. Several third-party investigations have shown that the precursor acid forms THC-A and THC-B in live cannabis leaf are inherently non-psychoactive and that the process of drying and heating the leaf metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential.
Roger Baylis-Duffield, Chief Executive Officer of Protext, commented, "Where most pharma companies have chosen to focus on the non-psychoactive CBD chemical, we believe that this strategy limits the potential medical benefits. Recent third party studies have demonstrated the synergistic value of retaining the full chemical profile of cannabis. Our objective is to validate Cannabis Biosciences cannabis extracts to be not only full profile but also non-psychoactive, which will give researchers all of the benefits of cannabis without the unwanted side effects. The acquisition of Cannabis Biosciences by Protext properly aligns our pharmaceutical research under one roof, allowing us to further our cannabis studies as we strive to create a cannabis extract that can increase the well-being and potentially improve the lives of so many people."
We encourage our investors and shareholders to connect and engage with us through social media. You can find us on the following;
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
About Protext Mobility, Inc. Protext Mobility, operates two wholly owned subsidiaries; Plandaí Biotechnology South Africa (SA) and Cannabis Biosciences. The Company is engaged in the research and clinical testing of "bioceutical" products -- all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Through its wholly owned subsidiary Plandaí Biotechnology SA, the Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex, which was developed by Plandaí Biotechnology, Inc. Phytofare® is a highly bioavailable extract produced from live green tea leaves. Our initial product, Phytofare® Catechin Complex, has been clinically shown to have 10 times greater bioavailability over generic catechin extracts. What this means is that Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours. Plandaí grows green tea on its 7,500 acre Senteeko estate in South Africa, where it produces the proprietary Phytofare® catechin extract in-house, allowing the Company a continuity of supply as well as quality control throughout the entire process. Targeted applications for the Company's products include arthritis, inflammation, anti-viral, and diabetes-related metabolic syndromes.
Please visit http://www.protextm.co for further information.
About Cannabis Biosciences The Company is actively pursuing government licenses and permits that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.
CONTACT INFORMATION
Protext Mobility, Inc.
Info@protextm.co
Contact: (435)881-3611
Source: Protext Mobility, Inc.
Strongly agree with you $TXTM
We did it my friend! enjoy this weeknd and be completely ready for next week... This would be pretty awesome!!!!!!!!
$TXTM
Cheers!!!! I can't wait for next week :P
Of course my bro! We are the $TXTM Musketeers!!! xD
Dimi u found me xD! I am so happy to see u around here too... I am here .0005. now I'm so excited about how is going up! This will be a fantastic weeknd as you said.. and next week BOOM!
$TXTM
congratz for u and everybody in here bro! ^^ we were and are fdoing really good!
$TXTM
now looking pretty beautiful xD!
Woooooohoooooooooo!!!!! now is our time :D
$TXTM
Patience, patience, patience... I'll be waiting soooo excited for next week :D $TXTM
$TXTM Next week is gonna be HUGEEEEE FOLKS!!!
$TXTM
My friends, get ready for this coming ride, the rocket is about to be launched...
$TXTM
Exactly my friend... people are getting ready for the ride! $TXTM
$TXTM This is very suspicious...
That is a good signal I think... ^^
Was some minutes ago, but the tweet was removed...
That's Right my friend! ;)
Business update/fact sheet posted on Investors page:
Business Summary / Fact Sheet
I hope monday this can be more great than today! :D $TXTM
yeah is good xD just that was funny xD $TXTM
xD incarnation lol. and nope! my last alias was Unknowns
stranger????
I completely agree with you doog! this is gonna run HUGEEEEE!!!!! $TXTM
I am so happy to stay in here! $TXTM
Hi dsoulliere, the post is stickied ;)... I am always in here, but i have a lot of things to do, sorry for that.. is everyone need something and I can help, just let me know, I'll be glad to help! ^^
$$$$$ TXTM $$$$$$